| Literature DB >> 29784590 |
J Sanz-Reig1, J Salvador Marín2, J Ferrández Martínez2, D Orozco Beltrán3, J F Martínez López2, J A Quesada Rico3.
Abstract
PURPOSE: The incidence of hip fractures is increasing within the aging population. Our objective was to identify and quantify the risk factors and develop a predictive model for the in-hospital mortality among hip fracture patients older than 65 years.Entities:
Keywords: Elder population; Hip fractures; In-hospital mortality; Prognostic factors
Mesh:
Year: 2018 PMID: 29784590 PMCID: PMC6033736 DOI: 10.1016/j.cjtee.2017.10.006
Source DB: PubMed Journal: Chin J Traumatol ISSN: 1008-1275
Characteristics of the study population [data are expressed as n (%)].
| Variables | In-hospital mortality | ||||
|---|---|---|---|---|---|
| Yes | No | ||||
| No. of patients | 331 | 38 | 293 | ||
| Age (years) | 83.7 (67–98) | 87.7 (81–97) | 83.2 (67–98) | <0.001 | |
| Age (years) | |||||
| ≤ 84 | 171 (51.7) | 13 (34.2) | 158 (53.9) | 0.05 | |
| 85-89 | 87 (26.3) | 12 (31.6) | 75 (25.6) | ||
| ≥ 90 | 73 (22.1) | 13 (34.2) | 60 (20.5) | ||
| Sex | |||||
| Male | 242 (73.1) | 15 (39.5) | 74 (25.3) | 0.07 | |
| Female | 89 (26.9) | 23 (60.5) | 219 (74.7) | ||
| Residence | |||||
| Home | 286 (86.4) | 33 (86.8) | 253 (86.4) | 0.61 | |
| Nursing | 45 (13.6) | 5 (13.2) | 40 (13.7) | ||
| Fracture pattern | |||||
| Femoral neck | 191 (57.7) | 17 (44.7) | 174 (59.4) | 0.21 | |
| Pertrochanteric | 124 (37.5) | 19 (50.0) | 105 (35.8) | ||
| Subtrochanteric | 16 (4.8) | 2 (5.3) | 14 (4.8) | ||
| Fracture pattern | |||||
| Intracapsular | 191 (57.7) | 17 (44.7) | 174 (59.4) | 0.11 | |
| Extracapsular | 140 (42.3) | 21 (55.3) | 119 (40.6) | ||
| Parker and Palmer score | 5.1 (1–9) | 3.4 (1–9) | 6.3 (4–9) | <0.001 | |
| Dependent mobility | 66 (19.9) | 23 (60.5) | 43 (14.7) | <0.001 | 8.9 (4.3–18.4) |
| Katz score | 4.7 (0–6) | 3.5 (0–6) | 5.4 (3–6) | <0.001 | |
| Dependence patients | 98 (29.6) | 28 (73.7) | 70 (23.9) | <0.001 | 8.9 (4.1–19.2) |
| Hemoglobin (g/L) | 125 (91–142) | 117 (91–128) | 123 (109–142) | 0.004 | |
| Hemoglobin (g/L) | |||||
| <100 | 30 (9.1) | 9 (23.7) | 21 (7.2) | 0.003 | 4.0 (1.6–9.5) |
| ≥100 | 301 (90.9) | 29 (76.3) | 272 (92.8) | ||
| Anticoagulant medication | 23 (7.0) | 3 (7.9) | 20 (6.8) | 0.73 | |
| Antiaggregant medication | 83 (25.1) | 2 (5.3) | 81 (27.7) | <0.001 | 0.14 (0.03–0.61) |
| Time to surgery (days) | 3.6 ± 2.1 | 4.1 ± 2.8 | 3.5 ± 2.0 | 0.36 | |
| Time to surgery > 2 days | 204/310 (65.8) | 15/24 (62.5) | 189/286 (66.1) | 0.44 | |
| Treatment | |||||
| | 310 (93.6) | 24 (63.1) | 286 (97.6) | <0.001 | 23.8 (8.7–64.6) |
| | 21 (6.4) | 14 (36.9) | 7 (2.4) | ||
| Surgical treatment | |||||
| | 177 (57.0) | 15 (62.5) | 162 (56.6) | 0.47 | |
| | 16 (5.1) | 0 | 16 (5.5) | ||
| | 117 (37.9) | 9 (37.5) | 108 (37.9) | ||
* Means and ranges.
Student's t-test.
Mann-Whitney U test.
Chi-square test.
Comorbidities at admission [data are expressed as n (%)].
| Comorbidities | In-hospital mortality | ||||
|---|---|---|---|---|---|
| Yes | No | ||||
| No. of patients | 331 | 38 | 293 | ||
| Hypertensive disease | 211 (63.8) | 24 (63.2) | 187 (63.8) | 1.0 | |
| Atrial fibrillation | 53 (16.0) | 8 (21.1) | 45 (15.4) | 0.35 | 3.3 (1.6–6.8) |
| Congestive heart failure | 63 (19.0) | 15 (39.5) | 48 (16.4) | 0.002 | |
| Ischemic heart disease | 55 (16.6) | 9 (23.7) | 46 (15.7) | 0.24 | |
| Cerebrovascular disease | 50 (15.1) | 8 (21.1) | 42 (14.3) | 0.33 | |
| Dementia | 97 (29.3) | 11 (29.0) | 86 (29.4) | 1.0 | |
| Epilepsy | 5 (1.5) | 1 (2.6) | 4 (1.4) | 0.45 | |
| Parkinson disease | 23 (7.0) | 3 (7.9) | 20 (6.8) | 0.73 | |
| Chronic obstructive pulmonary disease | 38 (11.5) | 7 (18.4) | 31 (10.6) | 0.17 | |
| Asthma | 11 (3.3) | 5 (13.2) | 6 (2.1) | 0.004 | 7.2 (2.0–25.0) |
| Diabetes | 83 (25.1) | 9 (23.7) | 74 (25.3) | 1.0 | |
| Rheumatologic disease | 15 (4.5) | 11 (29.0) | 4 (1.4) | <0.001 | 29.4 (8.7–98.7) |
| Renal disease | 21 (6.3) | 0 | 21 (7.2) | 0.14 | |
| Lung cancer | 10 (3.0) | 6 (15.8) | 4 (1.4) | <0.001 | 13.5 (3.6–50.5) |
| Peripheral vascular disease | 2 (0.6) | 0 | 2 (0.7) | ||
| Ulcer disease | 4 (1.2) | 1 (2.6) | 3 (1.0) | ||
| Liver disease | 1 (0.3) | 0 | 1 (0.3) | ||
| Leukemia | 0 | 0 | 0 | ||
| Lynfoma | 1 (0.3) | 0 | 1 (0.3) | ||
| Metastatic solid tumor | 0 | 0 | 0 | ||
| AIDS | 0 | 0 | 0 | ||
| Number of comorbidities* | 3.5 (1–7) | 4.5 (3–7) | 3.1 (1–7) | <0.001 | |
| Number of comorbidities> 2 | 208 (62.8) | 32 (84.2) | 176 (60.1) | 0.002 | 3.5 (1.4–8.7) |
| CCI* | 2.4 (1–7) | 3.9 (3–7) | 2.5 (1–7) | <0.001 | |
| CCI > 2 | 129 (39.0) | 26 (68.4) | 103 (35.2) | <0.001 | 3.9 (1.9–8.2) |
| Age-adjusted CCI* | 5.3 (2–10) | 6.4 (4–10) | 5.2 (2–10) | <0.001 | |
| Age-adjusted CCI > 6 | 132 (39.9) | 29 (76.3) | 103 (35.2) | <0.001 | 5.9 (2.7–3.0) |
*Means and ranges.
CCI: Charlson Comorbidity Index.
Chi square test.
Student's t-test.
Multivariate analysis for in-hospital mortality.
| Variables | 95% | ||
|---|---|---|---|
| Age | 1.2 | 1.1–1.3 | 0.004 |
| Sex (Female/Male) | |||
| 2.5 | 0.8–8.1 | 0.112 | |
| Congestive heart failure (No/Yes) | |||
| 6.2 | 1.8–20.9 | 0.003 | |
| Asthma (No/Yes) | |||
| 101.3 | 12.0–851.5 | <0.001 | |
| Rheumatologic disease (No/Yes) | |||
| 73.4 | 13.1–410.1 | <0.001 | |
| Lung cancer (No/Yes) | |||
| 74.9 | 9.1–619.1 | <0.001 | |
| Anti-aggregant medication (No/Yes) | |||
| 150.6 | 4.7–4814.7 | 0.005 |
Fig. 1Receiver-operating characteristic (ROC) curve and corresponding area under the curve (AUC) with 95% CI for in-hospital mortality in patients with hip fracture.
Model predicted values.
| 95% | ||
|---|---|---|
| Sensitivity (%) | 56.7 | 37.4–74.5 |
| Specificity (%) | 99.0 | 97.0–99.8 |
| True positive (%) | 0.05 | |
| True negative (%) | 87.3 | |
| False positive (%) | 0.009 | |
| False negative (%) | 0.03 | |
| Positive predictive value (%) | 85.0 | |
| Negative predictive value (%) | 95.7 | |
| Positive likelihood ratio | 56.7 | 17.1–177.4 |
| Negative likelihood ratio | 0.43 | 0.3–0.7 |
| 1/Negative likelihood ratio | 2.28 | 1.4–3.3 |
Risk score of in-hospital mortality after hip fracture.
| Variables | Points |
|---|---|
| Age | |
| 60-69 | 0 |
| 70-79 | 2 |
| 80-89 | 4 |
| 90-99 | 6 |
| 100-109 | 8 |
| Sex | |
| Female | 0 |
| Male | 1 |
| Congestive heart failure | |
| No | 0 |
| Yes | 2 |
| Asthma | |
| No | 0 |
| Yes | 6 |
| Rheumatologic disease | |
| No | 0 |
| Yes | 6 |
| Lung cancer | |
| No | 0 |
| Yes | 6 |
| Anti-aggregant medication | |
| Yes | 0 |
| No | 7 |
Risk score and the incidence of estimated death.
| Point total | Estimate of risk (%) |
|---|---|
| ≤10 | ≤1 |
| 11 | 2.2 |
| 12 | 4.6 |
| 13 | 9.4 |
| 14 | 18.3 |
| 15 | 32.6 |
| 16 | 51.1 |
| 17 | 69.3 |
| 18 | 83.0 |
| 19 | 91.3 |
| ≥20 | >95.5 |